ClearLLab 10C - ZH - 中文版

目录

滤泡性淋巴瘤. ............................................................. 226 10 号病例滤泡性淋巴瘤........................................ 226 生发中心源性 B 细胞淋巴瘤. ....................................... 250 11 号病例生发中心源性 B 细胞淋巴瘤.................. 250 成熟 B 细胞淋巴瘤....................................................... 274 12 号病例成熟 B 细胞淋巴瘤................................ 274 成熟 B 细胞淋巴瘤....................................................... 298 13 号病例成熟 B 细胞淋巴瘤................................ 298 T 细胞源性肿瘤生成过程.................................................322 T 细胞成淋巴细胞性白血病/成淋巴细胞性淋巴瘤........ 322 14 号病例T 细胞成淋巴细胞性白血病/. T 细胞成淋巴细胞性淋巴瘤.................................. 322 T 细胞成淋巴细胞性白血病/成淋巴细胞性淋巴瘤........ 346 15 号病例T 细胞成淋巴细胞性白血病/. T 细胞成淋巴细胞性淋巴瘤.................................. 346 T 大颗粒淋巴瘤. .......................................................... 370 16 号病例：T 细胞淋巴组织增生性疾病................. 370 T 大颗粒淋巴瘤. .......................................................... 394 17 号病例：T 细胞淋巴组织增生性疾病................. 394 骨髓源性肿瘤生成过程....................................................418 急性髓性白血病........................................................... 418 18 号病例：急性髓性白血病.................................. 418 急性髓性白血病........................................................... 442 19 号病例：急性单核细胞白血病........................... 442 急性髓性白血病........................................................... 466 20 号病例：急性髓性白血病-NOS. ........................ 466 急性髓性白血病........................................................... 490 21 号病例：急性早幼粒细胞白血病. ...................... 490 急性髓性白血病........................................................... 514 22 号病例：急性单核细胞白血病........................... 514 骨髓增生异常综合征.................................................... 538 23 号病例：骨髓增生异常综合征........................... 538 骨髓增生异常综合征.................................................... 562 24 号病例：骨髓增生异常综合征........................... 562

引言. .................................................................................3 背景. .................................................................................3 免疫表型分型的共识建议....................................................4 ClearLLab 10C 方案组预期用途..........................................4 ClearLLab 10C 方案组. ......................................................4 ClearLLab 补偿套件...........................................................5 病例选择和分析..................................................................5 相关文档............................................................................6 参考文献............................................................................6 病例. .................................................................................7 未见免疫表型异常. .............................................................7 外周全血.......................................................................... 7 1 号病例：正常全血................................................... 7 骨髓............................................................................... 32 2 号病例：正常骨髓................................................. 32 淋巴结........................................................................... 56 3 号病例：正常淋巴结. ............................................ 56 B 细胞源性肿瘤生成过程...................................................80 B 成淋巴细胞性白血病/成淋巴细胞性淋巴瘤................. 80 4 号病例B 细胞急性成淋巴细胞性白血病/. 成淋巴细胞性淋巴瘤. ............................................. 80 B 成淋巴细胞性白血病/成淋巴细胞性淋巴瘤............... 105 5 号病例B 细胞急性成淋巴细胞性白血病/. 成淋巴细胞性淋巴瘤. ........................................... 105 慢性淋巴细胞白血病/小淋巴细胞淋巴瘤. .................... 130 6 号病例慢性淋巴细胞白血病/. 小淋巴细胞淋巴瘤................................................ 130 慢性淋巴细胞白血病/小淋巴细胞淋巴瘤. .................... 154 7 号病例慢性淋巴细胞白血病/. 小淋巴细胞淋巴瘤................................................ 154 被套细胞淋巴瘤........................................................... 178 8 号病例被套细胞淋巴瘤...................................... 178 浆细胞骨髓瘤. ............................................................. 202 9 号病例浆细胞骨髓瘤.......................................... 202

分析无小事

2 Beckman Coulter • ClearLLab 10C 方案组• C33371 AB